52 related articles for article (PubMed ID: 26629888)
1. A Systems Oncology Approach Identifies NT5E as a Key Metabolic Regulator in Tumor Cells and Modulator of Platinum Sensitivity.
Nevedomskaya E; Perryman R; Solanki S; Syed N; Mayboroda OA; Keun HC
J Proteome Res; 2016 Jan; 15(1):280-90. PubMed ID: 26629888
[TBL] [Abstract][Full Text] [Related]
2. ENTPD1 (CD39) and NT5E (CD73) expression in human glioblastoma: an in silico analysis.
Braganhol E; de Andrade GPB; Santos GT; Stefani MA
Purinergic Signal; 2024 Jun; 20(3):285-289. PubMed ID: 37402102
[TBL] [Abstract][Full Text] [Related]
3. Loss of CD73-mediated actin polymerization promotes endometrial tumor progression.
Bowser JL; Blackburn MR; Shipley GL; Molina JG; Dunner K; Broaddus RR
J Clin Invest; 2016 Jan; 126(1):220-38. PubMed ID: 26642367
[TBL] [Abstract][Full Text] [Related]
4. CD73 as a therapeutic target for pancreatic neuroendocrine tumor stem cells.
Katsuta E; Tanaka S; Mogushi K; Shimada S; Akiyama Y; Aihara A; Matsumura S; Mitsunori Y; Ban D; Ochiai T; Kudo A; Fukamachi H; Tanaka H; Nakayama K; Arii S; Tanabe M
Int J Oncol; 2016 Feb; 48(2):657-69. PubMed ID: 26691441
[TBL] [Abstract][Full Text] [Related]
5. Antitumor effect of combined NAMPT and CD73 inhibition in an ovarian cancer model.
Sociali G; Raffaghello L; Magnone M; Zamporlini F; Emionite L; Sturla L; Bianchi G; Vigliarolo T; Nahimana A; Nencioni A; Raffaelli N; Bruzzone S
Oncotarget; 2016 Jan; 7(3):2968-84. PubMed ID: 26658104
[TBL] [Abstract][Full Text] [Related]
6. Downregulation of CD73 in 4T1 breast cancer cells through siRNA-loaded chitosan-lactate nanoparticles.
Jadidi-Niaragh F; Atyabi F; Rastegari A; Mollarazi E; Kiani M; Razavi A; Yousefi M; Kheshtchin N; Hassannia H; Hadjati J; Shokri F
Tumour Biol; 2016 Jun; 37(6):8403-12. PubMed ID: 26733167
[TBL] [Abstract][Full Text] [Related]
7. Effects of CD73 on human colorectal cancer cell growth in vivo and in vitro.
Wu R; Chen Y; Li F; Li W; Zhou H; Yang Y; Pei Z
Oncol Rep; 2016 Mar; 35(3):1750-6. PubMed ID: 26708311
[TBL] [Abstract][Full Text] [Related]
8. Ovarian cancer stem cells more questions than answers.
Ottevanger PB
Semin Cancer Biol; 2017 Jun; 44():67-71. PubMed ID: 28450177
[TBL] [Abstract][Full Text] [Related]
9. Targeting metabolic fluxes reverts metastatic transitions in ovarian cancer.
Arora G; Banerjee M; Langthasa J; Bhat R; Chatterjee S
iScience; 2023 Nov; 26(11):108081. PubMed ID: 37876796
[TBL] [Abstract][Full Text] [Related]
10. The Clinical Significance of CD73 in Cancer.
Bach N; Winzer R; Tolosa E; Fiedler W; Brauneck F
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511518
[TBL] [Abstract][Full Text] [Related]
11. Notch1 promotes resistance to cisplatin by up-regulating Ecto-5'-nucleotidase (CD73) in triple-negative breast cancer cells.
Qi Y; Li M; Li S; Zeng D; Xiao Y; Li J; Ye Q; Bremer E; Zhang GJ
Cell Death Discov; 2023 Jun; 9(1):204. PubMed ID: 37391408
[TBL] [Abstract][Full Text] [Related]
12. Transcriptomics, proteomics, metabolomics and network pharmacology reveal molecular mechanisms of multi-targets effects of Shenxianshengmai improving human iPSC-CMs beating.
Hu Y; Chen L; Zhao S; Feng R; Cao X; Chen G; Zhao T; Zhang C; Fang Z; Guo Z; Yu X; Zhang Z; Abdurahman M; Hong H; He Y; Li H
Clin Transl Med; 2023 Jun; 13(6):e1302. PubMed ID: 37282796
[No Abstract] [Full Text] [Related]
13. Analysis of a large cohort of pancreatic cancer transcriptomic profiles to reveal the strongest prognostic factors.
Posta M; Győrffy B
Clin Transl Sci; 2023 Aug; 16(8):1479-1491. PubMed ID: 37260110
[TBL] [Abstract][Full Text] [Related]
14. Integration of multi-omics data reveals a novel hybrid breast cancer subtype and its biomarkers.
Wang ZZ; Li XH; Wen XL; Wang N; Guo Y; Zhu X; Fu SH; Xiong FF; Bai J; Gao XL; Wang HJ
Front Oncol; 2023; 13():1130092. PubMed ID: 37064087
[TBL] [Abstract][Full Text] [Related]
15. Targeting purine metabolism in ovarian cancer.
Liu J; Hong S; Yang J; Zhang X; Wang Y; Wang H; Peng J; Hong L
J Ovarian Res; 2022 Aug; 15(1):93. PubMed ID: 35964092
[TBL] [Abstract][Full Text] [Related]
16. Targeting SIRT2 Sensitizes Melanoma Cells to Cisplatin via an EGFR-Dependent Mechanism.
Karwaciak I; Sałkowska A; Karaś K; Dastych J; Ratajewski M
Int J Mol Sci; 2021 May; 22(9):. PubMed ID: 34068624
[TBL] [Abstract][Full Text] [Related]
17. High-dimensional analysis of the adenosine pathway in high-grade serous ovarian cancer.
Bareche Y; Pommey S; Carneiro M; Buisseret L; Cousineau I; Thebault P; Chrobak P; Communal L; Allard D; Robson SC; Mes-Masson AM; Provencher D; Lapointe R; Stagg J
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33771891
[TBL] [Abstract][Full Text] [Related]
18. CD73, Tumor Plasticity and Immune Evasion in Solid Cancers.
Yang H; Yao F; Davis PF; Tan ST; Hall SRR
Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33430239
[TBL] [Abstract][Full Text] [Related]
19. Targeting CD73 to augment cancer immunotherapy.
Roh M; Wainwright DA; Wu JD; Wan Y; Zhang B
Curr Opin Pharmacol; 2020 Aug; 53():66-76. PubMed ID: 32777746
[TBL] [Abstract][Full Text] [Related]
20. Targeting Adenosine in Cancer Immunotherapy to Enhance T-Cell Function.
Vigano S; Alatzoglou D; Irving M; Ménétrier-Caux C; Caux C; Romero P; Coukos G
Front Immunol; 2019; 10():925. PubMed ID: 31244820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
